Physician profile
Michael J Doherty
NPI 1528043080
$2,587.82
in general payments reported to CMS, 2019-2025
24 companies · $280 in 2025
The $280 reported for 2025 was more than what 86% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $44.09 · 2020: $150 · 2021: $400 · 2022: $469 · 2023: $643 · 2024: $602 · 2025: $280.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,524.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,524.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $420.69 | 2020-2024 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $397.44 | 2021-2025 | Simponi Aria, Stelara, Simponi |
| Abbvie INC. | $292.07 | 2020-2025 | |
| Redhill Biopharma INC. | $268.34 | 2021-2023 | Talicia, Movantik, Aemcolo |
| Nestle Healthcare Nutrition INC. | $206.71 | 2021-2023 | |
| Lilly USA, LLC | $147.64 | 2024-2025 | Omvoh |
| Takeda Pharmaceuticals U.S.A., INC. | $120.59 | 2021-2024 | Entyvio |
| Intercept Pharmaceuticals, INC. | $85.49 | 2021-2024 | Ocaliva |
| Ardelyx, INC. | $85.49 | 2022-2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $80.00 | 2021-2022 | |
| Ironwood Pharmaceuticals, INC | $76.80 | 2022-2023 | Linzess |
| Evoke Pharma, INC. | $45.52 | 2023-2024 | Gimoti |
| Shionogi INC | $44.71 | 2019-2020 | |
| Boston Scientific Corporation | $40.93 | 2019-2024 | |
| Braintree Laboratories, INC. | $39.48 | 2021-2023 | Sutab |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $39.28 | 2024-2025 | Vegzelma |
| Intuitive Surgical, INC. | $38.21 | 2021 | |
| Madrigal Pharmaceuticals | $32.59 | 2025 | Rezdiffra |
| Laborie Medical Technologies Corp. | $30.06 | 2023 | |
| Ipsen Biopharmaceuticals, INC | $28.31 | 2024 | Iqirvo |
| Phathom Pharmaceuticals, INC. | $23.23 | 2024 | Voquezna |
| Biogen, INC. | $18.20 | 2024 | Skyclarys |
| Aimmune Therapeutics, INC. | $13.49 | 2024 | |
| Hologic Sales and Service, LLC | $12.55 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Doherty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.